Mapping the p53 transcriptome universe using p53 natural polymorphs

Cell Death and Differentiation

Volumn 21, Issue 4, 2014, Pages 521-532

  Wang, B ^a   Niu, D ^a   Lam, T H ^a,b   Xiao, Z ^a   Ren, E C ^a,b  

^a AGENCY FOR SCIENCE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

cancer; p53; single nucleotide polymorphisms; transcriptome

Indexed keywords

DNA; PROTEIN P53; TRANSCRIPTOME;

ARTICLE; CENTRAL NERVOUS SYSTEM; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DNA STRUCTURE; GENE IDENTIFICATION; GENE MAPPING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IMMUNE SYSTEM; METABOLISM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TECHNOLOGY; WILD TYPE;

ANTIBIOTICS, ANTINEOPLASTIC; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DNA; DOXORUBICIN; GENE REGULATORY NETWORKS; HCT116 CELLS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA; STAT4 TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903362301     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.132     Document Type: Article

References (41)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
2. Menendez D, Inga A, Resnick MA. The expanding universe of p53 targets. Nat Rev Cancer 2009; 9: 724-737.
3. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
4. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006; 126: 107-120.
5. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 2007; 21: 562-577.
6. Brady CA, Attardi LD. p53 at a glance. J Cell Sci 2010; 123: 2527-2532.
7. Ma B, Pan Y, Zheng J, Levine AJ, Nussinov R. Sequence analysis of p53 responseelements suggests multiple binding modes of the p53 tetramer to DNA targets. Nucleic Acids Res 2007; 35: 2986-3001.
8. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
9. Wang B, Xiao Z, Ren EC. Redefining the p53 response element. Proc Natl Acad Sci USA 2009; 106: 14373-14378.
10. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
11. NCBI SNP database [http://www.ncbi.nlm.nih.gov/projects/SNP/].
12. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor- DNA complex: understanding tumorigenic mutations. Science 1994; 265: 346-355.
13. Saramaki A, Banwell CM, Campbell MJ, Carlberg C. Regulation of the human p21 (waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Res 2006; 34: 543-554.
14. Jen KY, Cheung VG. Identification of novel p53 target genes in ionizing radiation response. Cancer Res 2005; 65: 7666-7673.
15. Ng CC, Arakawa H, Fukuda S, Kondoh H, Nakamura Y. p53RFP, a p53-inducible RINGfinger protein, regulates the stability of p21WAF1. Oncogene 2003; 22: 4449-4458.
16. Benchimol S. p53-dependent pathways of apoptosis. Cell Death Differ 2001; 8: 1049-1051.
17. Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T. A global map of p53 transcription-factor binding sites in the human genome. Cell 2006; 124: 207-219.
18. Nikulenkov F, Spinnler C, Li H, Tonelli C, Shi Y, Turunen M et al. Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis. Cell Death Differ 2012; 19: 1992-2002.
19. Norremolle A, Riess O, Epplen JT, Fenger K, Hasholt L, Sørensen SA. Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet 1993; 2: 1475-1476.
20. Shiels A, Bennett TM, Knopf HL, Maraini G, Li A, Jiao X et al. The EPHA2 gene is associated with cataracts linked to chromosome 1p. Mol Vis 2008; 14: 2042-2055.
21. Kim CA, Delepine M, Boutet E, El Mourabit H, Le Lay S, Meier M et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. J Clin Endocrinol Metab 2008; 93: 1129-1134.
22. Milunsky JM, Maher TA, Zhao G, Roberts AE, Stalker HJ, Zori RT et al. TFAP2A mutations result in branchio-oculo-facial syndrome. Am J Hum Genet 2008; 82: 1171-1177.
23. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
24. Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C et al. STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma production but not for cell proliferation. Proc Natl Acad Sci USA 2002; 99: 12281-12286.
25. Thierfelder WE, van Deursen JM, Yamamoto K, Tripp RA, Sarawar SR, Carson RT et al. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 1996; 382: 171-174.
26. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1: 45-49.
27. Miled C, Pontoglio M, Garbay S, Yaniv M, Weitzman JB. A genomic map of p53 binding sites identifies novel p53 targets involved in an apoptotic network. Cancer Res 2005; 65: 5096-5104.
28. Wang L, Wu Q, Qiu P, Mirza A, McGuirk M, Kirschmeier P et al. Analyses of p53 target genes in the human genome by bioinformatic and microarray approaches. J Biol Chem 2001; 276: 43604-43610.
29. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
30. Lee ML, Kuo FC, Whitmore GA, Sklar J. Importance of replication in microarray gene expression studies: statistical methods and evidence from repetitive cDNA hybridizations. Proc Natl Acad Sci USA 2000; 97: 9834-9839.
31. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 2011; 145: 571-583.
32. O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL. Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res 2004; 64: 8199-8207.
33. Scian MJ, Stagliano KE, Ellis MA, Hassan S, Bowman M, Miles MF et al. Modulation of gene expression by tumor-derived p53 mutants. Cancer Res 2004; 64: 7447-7454.
34. Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood 2009; 113: 4016-4026.
35. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6: 836-848.
36. Kim KS, Kang KW, Seu YB, Baek SH, Kim Jr. Interferon-gamma induces cellular senescence through p53-dependent DNA damage signaling in human endothelial cells. Mech Ageing Dev 2009; 130: 179-188.
37. Munoz-Fontela C, Macip S, Martinez-Sobrido L, Brown L, Ashour J, García-Sastre A et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205: 1929-1938.
38. Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003; 424: 516-523.
39. Wang B, Feng P, Xiao Z, LIM Ren EC. and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol 2009; 50: 528-537.
40. Langmead B, Trapnell C, Pop M, Salzberg SL. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
41. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol 2008; 9: R137.